Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision vs Conventional Infliximab Dosing in IBD
NCT02453776Phase 4
Key facts
- Status
- Completed
- Start
- May 2015
- Primary completion
- Dec 2018
- Countries
- 1
- Sponsor
- University of Amsterdam
- Modality
- Monoclonal Antibodies
- Drugs
- infliximab
- Conditions
- inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
01
Overview
Phase 4, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC), sponsored by University of Amsterdam. Primary endpoint: Sustained clinical remission at 52 weeks. Started May 2015; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Adults with CD or UC in clinical remission (HBI <=4 or PM <=2) receiving scheduled infliximab maintenance for at least 14 weeks.
04
Endpoints
Primary
Sustained clinical remission
Secondary
Annual costs of infliximab treatment
Beyond the preview
Go deeper on NCT02453776.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453776.